TORONTO and WINNIPEG, Aug. 13 /CNW/ - Cangene Corporation today reports that it has met all the regulatory and manufacturing requirements for the “Usable Product” milestone on contracts with the U.S. government for products to treat botulism and inhalational anthrax. The contracts, the largest in Cangene history, were signed last year and are managed by the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) within the Department of Health and Human Services (“HHS”). The Usable Product designation means the Company has met specific regulatory and manufacturing requirements that allow it to deliver the products to the U.S. Strategic National Stockpile and begin invoicing once delivery has been accepted.
